131 / 140
Principios generales de tratamiento particularizado de los sarcomas de partes blandas según histología
>
131
Sarcomas del desarrollo
Sarcoma de Ewing
167. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmeta-
static Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664.
168. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for
Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694.
169. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemo- therapy for nonmet-
astatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 2009;27:2536-41.
170. Womer RB, West DC, Krailo MD, et al. Randomized Controlled Trial of Interval-Compressed Chemotherapy
for the Treatment of Localized Ewing Sarcoma: A Report From the Children’s Oncology Group. J Clin Oncol
2012;30(33):4148-15.
171. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing’s sarcoma/
primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experi-
ence and a literature review. J Clin Oncol 2001;19:870-80.
172. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective reg-
imen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol
1987;5:1191.
173. Morland B, Platt K, Whelan JS. A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma:
a Euro-E.W.I.N.G. study. Pediatr Blood Cancer 2014;61:442.
174. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of ad-
vanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-9.
175. Saylors 3
rd
RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or
refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-9.
176. Mora J, Cruz CO, Parareda A, et al. Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine
and Docetaxel. J Pediatr Hematol Oncol 2009;31:723-9.
177. Hernando-Cubero J, Sanz-Moncasi P, Hernández-García A, et al. Metastatic extraskeletal Ewing's sarcoma
treated with trabectedin: A case report. Oncol Lett 2016;12:2936-41.
178. Attia S, Okuno S, Robinson S, et al. Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma.
Rare Tumors 2015;7:5992.
179. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 re-
ceptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011;29:4534-40.
180. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 re-
ceptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma
Alliance for Research through Collaboration study. J Clin Oncol 2011;29:4541-7.
181. Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer
Res 2012;72:1608-13.
182. Choy E, Butrynski J, Harmon D, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma
following failure of standard chemotherapy. BMC Cancer 2014;14:813.
Rabdomiosarcoma
183. Malempati S, Hawkins D. Rhabdomyosarcoma: Review of the Children’s Oncology Group (COG) Soft-Tissue
Sarcoma Committee Experience and Rationale for Current COG Studies. Pediatr Blood Cancer 2012;59:5.
184. Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group
D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy,
for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sar-
coma Committee of the Children's Oncology Group. J Clin Oncol 2011;29:1312.
185. David O, Walterhouse, Alberto S, et al. Shorter-Duration Therapy Using Vincristine, Dactinomycin, and
Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With NewlyDiagnosed Low-Risk
Rhabdomyosarcoma: A Report Fromthe Soft Tissue Sarcoma Committee of the Children’s Oncology Group.
J Clin Oncol 2014;32:3547-52.